Literature DB >> 24644133

Proficiency of nerve conduction using standard methods and reference values (Cl. NPhys Trial 4).

William J Litchy1, James W Albers, James Wolfe, Charles F Bolton, Nancy Walsh, Christopher J Klein, Andrew J Zafft, James W Russell, Melanie Zwirlein, Carol J Overland, Jenny L Davies, Rickey E Carter, Peter J Dyck.   

Abstract

INTRODUCTION: The Cl. NPhys Trial 3 showed that attributes of nerve conduction (NC) were without significant intraobserver differences, although there were significant interobserver differences.
METHODS: Trial 4 tested whether use of written instructions and pretrial agreement on techniques and use of standard reference values, diagnostic percentile values, or broader categorization of abnormality could reduce significant interobserver disagreement and improve agreement among clinical neurophysiologists.
RESULTS: The Trial 4 modifications markedly decreased, but did not eliminate, significant interobserver differences of measured attributes of NC. Use of standard reference values and defined percentile values of abnormality decreased interobserver disagreement and improved agreement of judgment of abnormality among evaluators. Therefore, the same clinical neurophysiologist should perform repeat NCs of therapeutic trial patients.
CONCLUSIONS: Differences in interobserver judgment of abnormality decrease with use of common standard reference values and a defined percentile level of abnormality, providing a rationale for their use in therapeutic trials and medical practice.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  multicenter trial; nerve conduction accuracy; nerve conduction proficiency; neuropathy impairment score; reference values

Mesh:

Year:  2014        PMID: 24644133      PMCID: PMC4169346          DOI: 10.1002/mus.24243

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  12 in total

1.  Inter- and intra-examiner reliability of nerve conduction measurements in normal subjects.

Authors:  V Chaudhry; D R Cornblath; E D Mellits; O Avila; M L Freimer; J D Glass; J Reim; G V Ronnett; S A Quaskey; R W Kuncl
Journal:  Ann Neurol       Date:  1991-12       Impact factor: 10.422

2.  Multicenter trial of the proficiency of smart quantitative sensation tests.

Authors:  Peter J Dyck; Barbara Argyros; James W Russell; Linde E Gahnstrom; Susan Nalepa; James W Albers; Karen A Lodermeier; Andrew J Zafft; P James B Dyck; Christopher J Klein; William J Litchy; Jenny L Davies; Rickey E Carter; L Joseph Melton
Journal:  Muscle Nerve       Date:  2014-01-28       Impact factor: 3.217

3.  "Unequivocally Abnormal" vs "Usual" Signs and Symptoms for Proficient Diagnosis of Diabetic Polyneuropathy: Cl vs N Phys Trial.

Authors:  Peter J Dyck; Carol J Overland; Phillip A Low; William J Litchy; Jenny L Davies; P James B Dyck; Rickey E Carter; L Joseph Melton; Henning Andersen; James W Albers; Charles F Bolton; John D England; Christopher J Klein; Gareth Llewelyn; Michelle L Mauermann; James W Russell; Dinesh Selvarajah; Wolfgang Singer; A Gordon Smith; Solomon Tesfaye; Adrian Vella
Journal:  Arch Neurol       Date:  2012-12

4.  Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.

Authors:  Dan Ziegler; Alexander Ametov; Alexey Barinov; Peter J Dyck; Irina Gurieva; Phillip A Low; Ullrich Munzel; Nikolai Yakhno; Itamar Raz; Maria Novosadova; Joachim Maus; Rustem Samigullin
Journal:  Diabetes Care       Date:  2006-11       Impact factor: 19.112

5.  Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group.

Authors:  S C Apfel; S Schwartz; B T Adornato; R Freeman; V Biton; M Rendell; A Vinik; M Giuliani; J C Stevens; R Barbano; P J Dyck
Journal:  JAMA       Date:  2000-11-01       Impact factor: 56.272

6.  Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial.

Authors:  Peter J Dyck; Carol J Overland; Phillip A Low; William J Litchy; Jenny L Davies; P James B Dyck; Peter C O'Brien; James W Albers; Henning Andersen; Charles F Bolton; John D England; Christopher J Klein; J Gareth Llewelyn; Michelle L Mauermann; James W Russell; Wolfgang Singer; A Gordon Smith; Solomon Tesfaye; Adrian Vella
Journal:  Muscle Nerve       Date:  2010-08       Impact factor: 3.217

7.  Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.

Authors:  John L Berk; Ole B Suhr; Laura Obici; Yoshiki Sekijima; Steven R Zeldenrust; Taro Yamashita; Michael A Heneghan; Peter D Gorevic; William J Litchy; Janice F Wiesman; Erik Nordh; Manuel Corato; Alessandro Lozza; Andrea Cortese; Jessica Robinson-Papp; Theodore Colton; Denis V Rybin; Alice B Bisbee; Yukio Ando; Shu-ichi Ikeda; David C Seldin; Giampaolo Merlini; Martha Skinner; Jeffery W Kelly; Peter J Dyck
Journal:  JAMA       Date:  2013-12-25       Impact factor: 56.272

8.  A trial of proficiency of nerve conduction: greater standardization still needed.

Authors:  Peter J Dyck; James W Albers; James Wolfe; Charles F Bolton; Nancy Walsh; Christopher J Klein; Andrew J Zafft; James W Russell; Karen Thomas; Jenny L Davies; Rickey E Carter; L Joseph Melton; William J Litchy
Journal:  Muscle Nerve       Date:  2013-07-17       Impact factor: 3.217

9.  Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects.

Authors:  P J Dyck; W J Litchy; K A Lehman; J L Hokanson; P A Low; P C O'Brien
Journal:  Neurology       Date:  1995-06       Impact factor: 9.910

10.  Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.

Authors:  Dan Ziegler; Phillip A Low; William J Litchy; Andrew J M Boulton; Aaron I Vinik; Roy Freeman; Rustem Samigullin; Hans Tritschler; Ullrich Munzel; Joachim Maus; Klemens Schütte; Peter J Dyck
Journal:  Diabetes Care       Date:  2011-07-20       Impact factor: 19.112

View more
  10 in total

Review 1.  Diabetic neuropathy: mechanisms, emerging treatments, and subtypes.

Authors:  James W Albers; Rodica Pop-Busui
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

Review 2.  Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.

Authors:  Peter J Dyck; Bruce V Taylor; Jenny L Davies; Michelle L Mauermann; William J Litchy; Christopher J Klein; P James B Dyck
Journal:  Muscle Nerve       Date:  2015-08-13       Impact factor: 3.217

3.  Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial.

Authors:  Peter J Dyck; John C Kincaid; P James B Dyck; Vinay Chaudhry; Namita A Goyal; Christina Alves; Hayet Salhi; Janice F Wiesman; Celine Labeyrie; Jessica Robinson-Papp; Márcio Cardoso; Matilde Laura; Katherine Ruzhansky; Andrea Cortese; Thomas H Brannagan; Julie Khoury; Sami Khella; Márcia Waddington-Cruz; João Ferreira; Annabel K Wang; Marcus V Pinto; Samar S Ayache; Merrill D Benson; John L Berk; Teresa Coelho; Michael Polydefkis; Peter Gorevic; David H Adams; Violaine Plante-Bordeneuve; Carol Whelan; Giampaolo Merlini; Stephen Heitner; Brian M Drachman; Isabel Conceição; Christopher J Klein; Morie A Gertz; Elizabeth J Ackermann; Steven G Hughes; Michelle L Mauermann; Rito Bergemann; Karen A Lodermeier; Jenny L Davies; Rickey E Carter; William J Litchy
Journal:  Muscle Nerve       Date:  2017-04-07       Impact factor: 3.217

4.  Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study.

Authors:  David Adams; Teresa Coelho; Laura Obici; Giampaolo Merlini; Zoia Mincheva; Narupat Suanprasert; Brian R Bettencourt; Jared A Gollob; Pritesh J Gandhi; William J Litchy; Peter J Dyck
Journal:  Neurology       Date:  2015-07-24       Impact factor: 9.910

Review 5.  Distal Sensorimotor Neuropathy: Improvements in Diagnosis.

Authors:  Prashanth R J Vas; Sanjeev Sharma; Gerry Rayman
Journal:  Rev Diabet Stud       Date:  2015-08-10

6.  Four-year sequential nerve conduction changes since first visit in Japanese patients with early type 2 diabetes.

Authors:  Mariko Kobori; Soroku Yagihashi; Norie Shiina; Nana Shiozawa; Akiko Haginoya; Misato Ojima; Satako Douguchi; Atsuko Tamasawa; Miyoko Saitou; Masayuki Baba; Takeshi Osonoi
Journal:  J Diabetes Investig       Date:  2016-12-09       Impact factor: 4.232

7.  Cardio-Ankle Vascular Index and Indices of Diabetic Polyneuropathy in Patients with Type 2 Diabetes.

Authors:  Akihiko Ando; Michiaki Miyamoto; Kazuhiko Kotani; Kenta Okada; Shoichiro Nagasaka; Shun Ishibashi
Journal:  J Diabetes Res       Date:  2017-05-09       Impact factor: 4.011

8.  Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.

Authors:  David Adams; Ole B Suhr; Peter J Dyck; William J Litchy; Raina G Leahy; Jihong Chen; Jared Gollob; Teresa Coelho
Journal:  BMC Neurol       Date:  2017-09-11       Impact factor: 2.474

Review 9.  Advances in Screening, Early Diagnosis and Accurate Staging of Diabetic Neuropathy.

Authors:  Josie Carmichael; Hassan Fadavi; Fukashi Ishibashi; Angela C Shore; Mitra Tavakoli
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-26       Impact factor: 5.555

10.  Inter-practitioner comparisons of nerve conduction studies with standardized techniques in normal subjects: Reap as you sow.

Authors:  Bing Zhao; Hong-Mei Diao; Qing-Xian Wen; Ke-Xv Sui; Yong-Qing Zhang
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.